J. Goldman & CO LP Aldeyra Therapeutics, Inc. Transaction History

J. Goldman & CO LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$6.11 - $8.16 $494,910 - $660,960	-81,000 Reduced 75.0%	27,000 $180,000
Q2 2023 Aug 14, 2023	BUY	$7.11 - $11.89 $482,235 - $806,439	67,825 Added 168.82%	108,000 $906,000
Q1 2023 May 15, 2023	SELL	$5.77 - $9.93 $3.56 Million - $6.12 Million	-616,370 Reduced 93.88%	40,175 $398,000
Q4 2022 Feb 14, 2023	BUY	$5.08 - $7.09 $1.65 Million - $2.3 Million	323,949 Added 97.4%	656,545 $4.57 Million
Q3 2022 Nov 14, 2022	BUY	$3.8 - $7.74 $1.26 Million - $2.57 Million	332,596 New	332,596 $1.78 Million

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $279M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

Stay updated on J. Goldman & CO LP with notifications on news.